SUPRIYA919.40

Supriya Lifescience Ltd.

· Pharma & Health
₹ CrorePeersSTARSPARCTHYROCARESHILPAMEDVIYASHRUBICONYATHARTHPARKHOSPS
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation11.815.820.4
+ Finance Costs3.1
+ Interest Income-9.5-10.0-7.9
Changes in Working Capital
+ Inventories-23.530.5-33.1
+ Trade Receivables — Current30.5-27.0-22.7
+ Trade Payables — Current15.3-4.715.0
Cash from Operating Activities
Profit Before Tax (per I/S)268.2
Cash from Operations (pre-tax)66.2113.3164.7
Cash from Operating Activities66.2113.3164.7
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)108.4145.7162.4
+ Disp of Fixed Assets0.5
+ Dividends Received — Investing0.00.0
+ Interest Received — Investing10.69.6
Cash from Investing Activities-133.1-173.6-152.2
Cash from Financing Activities
+ Payment of Lease Liabilities0.30.40.1
+ Dividends Paid4.84.8
Cash from Financing Activities-3.4-22.4-8.2
Net Changes in Cash-70.3-82.64.2
Closing Cash227.9157.675.0
Reference Items
EBITDA289.8
EBITDA Margin %33.21
Free Cash Flow (CFO − Capex)-42.3-32.32.32.3
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 89%.